Anti-Rat IFNγ
| Code | Size | Price |
|---|
| LEI-I-233-25ug | 25 ug | £420.00 |
Quantity:
| LEI-I-233-100ug | 100 ug | £694.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Caprine (Goat)
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Immunocytochemistry (ICC)
- Neutralisation
- Western Blot (WB)
Shipping:
Ambient
Storage:
The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.
Further Information
Conjugate/Tag/Label:
Antigen Affinity Purified
Format:
This antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.
Formulation:
This antigen affinity purified polyclonal antibody has been 0.2 um filtered and lyophilized from modified Dulbecco?s phosphate buffered saline (1X PBS) pH 7.2 ? 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.
Immunogen:
Purified Recombinant Rat IFN-γ (>98%)
Long Description:
Interferon-gamma (IFN-γ) or type II interferon is a dimerized soluble cytokine that is the only member of the type II class of interferons.1 It is a cytokine critical for innate and adaptive immunity against viral and intracellular bacterial infections and for tumor control. IFNG is produced predominantly by natural killer (NK) and natural killer T (NKT) cells as part of the innate immune response, and by CD4 and CD8 cytotoxic T lymphocyte (CTL) effector T cells once antigen-specific immunity develops.2 IFN-γ has antiviral, immunoregulatory, and anti-tumour properties.3
NCBI Gene:
25712
Target:
IFN gamma
References
1. Goeddel, DV. et al. (1982) Nature 298: 859
2. Wilson, CB. et al. (2007) Adv. Immunol. 96: 41
3. Hume, DA. et al. (2004) J Leukoc Biol. 75: 163
Related Products
| Product Name | Product Code | Supplier | Anti-Human IFNγ | LEI-I-141 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recombinant Human IFNγ | LEI-I-179 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Rat IFNγ | LEI-I-223 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse IFNγ | LEI-I-232 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human CD119 (IFN-γ Rα Chain) | LEI-I-600 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Mouse IFNγ R2 | LEI-I-605 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Rat IFNγ (Clone 88915) | LEI-I-683 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Rat Interferon gamma (IFNγ) | LEI-R1365 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||